Lung cancer · Diagnostics

Making every lung biopsy count.

Cymantic Medical is developing real-time tissue analysis for the procedure room, so clinicians know they've got what they need before the patient goes home.

Find out why it matters

Why we exist

A biopsy should be the start of treatment, not the start of another wait.

When someone is told they might have lung cancer, a biopsy is the step that turns a suspicion into an answer. But whether that sample is good enough to diagnose usually isn't known until days or weeks later, in a lab, long after the procedure has ended.

When it isn't, the patient has to come back and go through it again, and the wait for treatment gets longer each time.

46% of lung cancer patients have multiple biopsies before a diagnosis¹

~3 in 4 lung cancers are found after they've already spread²

40–80% more cost when a lung biopsy has to be repeated³

What we do

Answers in the room, not days or weeks later.

We're building technology that gives clinical teams a clear read on a biopsy sample during the procedure, while there's still time to act on it.

In development. Not approved for clinical use in any jurisdiction.

For patients

Fewer repeat procedures and a shorter road from first scan to treatment.
For clinicians

Confidence before the procedure ends that it has delivered what's needed.
For hospitals

Procedure slots, staff time and lab capacity freed up for the next patient.